ARID1A deficiency is targetable by AKT inhibitors in HER2-negative gastric cancer-Reference-Cited by-同舟云学术

ARID1A deficiency is targetable by AKT inhibitors in HER2-negative gastric cancer

Published:2023-02-22 Issue:3 Volume:26 Page:379-392
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Sato Takahiro,Saito Motonobu^ORCID,Nakajima Shotaro,Saito Katsuharu,Katagata Masanori,Fukai Satoshi,Okayama Hirokazu,Sakamoto Wataru,Saze Zenichiro,Momma Tomoyuki,Mimura Kosaku,Kono Koji

Funder

JSPS KAKENHI

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10120-023-01373-6.pdf

Reference44 articles.

1. Jim MA, Pinheiro PS, Carreira H, Espey DK, Wiggins CL, Weir HK. Stomach cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):4994–5013.

2. Taniyama Y, Katanoda K, Charvat H, Hori M, Ohno Y, Sasazuki S, et al. Estimation of lifetime cumulative incidence and mortality risk of gastric cancer. Jpn J Clin Oncol. 2017;47:1097–102.

3. Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020;23:565–78.

4. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

5. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer;World Journal of Gastrointestinal Oncology;2024-06-15